Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Shares Issued (2018 - 2023)

VYNE Therapeutics (VYNE) has disclosed Shares Issued for 6 consecutive years, with $156000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Shares Issued fell 89.98% year-over-year to $156000.0, compared with a TTM value of $156000.0 through Dec 2023, down 89.39%, and an annual FY2023 reading of $156000.0, down 89.39% over the prior year.
  • Shares Issued was $156000.0 for Q1 2023 at VYNE Therapeutics, up from -$1000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $73.1 million in Q1 2021 and bottomed at -$86000.0 in Q2 2022.
  • Average Shares Issued over 5 years is $5.2 million, with a median of $82000.0 recorded in 2020.
  • The sharpest move saw Shares Issued tumbled 2100.0% in 2020, then soared 52133.57% in 2021.
  • Year by year, Shares Issued stood at $321000.0 in 2019, then plummeted by 60.12% to $128000.0 in 2020, then plummeted by 122.66% to -$29000.0 in 2021, then soared by 96.55% to -$1000.0 in 2022, then soared by 15700.0% to $156000.0 in 2023.
  • Business Quant data shows Shares Issued for VYNE at $156000.0 in Q1 2023, -$1000.0 in Q4 2022, and -$86000.0 in Q2 2022.